Biotest (LSE:0N70) - Stock Price, News & Analysis

0N70 Stock Overview

Develops, manufactures, and sells biological and biotechnological pharmaceutical products in Germany and internationally. More details

0N70 fundamental analysis
Snowflake Score
Valuation	4/6
Future Growth	4/6
Past Performance	1/6
Financial Health	2/6
Dividends	0/6

Rewards

Trading at 71.6% below our estimate of its fair value

Earnings are forecast to grow 29.3% per year

Risk Analysis

Interest payments are not well covered by earnings

Shares are highly illiquid

Profit margins (9.7%) are lower than last year (13.9%)

Large one-off items impacting financial results

Biotest Aktiengesellschaft Competitors

Genus

LSE:GNS

UK£1.1b

Bioventix

AIM:BVXP

UK£193.6m

Ergomed

AIM:ERGO

UK£701.1m

Hikma Pharmaceuticals

LSE:HIK

UK£4.2b

Price History & Performance

Summary of all time highs, changes and price drops for Biotest
Historical stock prices
Current Share Price	€27.49
52 Week High	€31.00
52 Week Low	€22.98
Beta	0.24
11 Month Change	-0.74%
3 Month Change	n/a
1 Year Change	-11.31%
33 Year Change	-30.22%
5 Year Change	27.88%
Change since IPO	135.67%

Recent updates

Shareholder Returns

	0N70	GB Biotechs	GB Market
7D	0%	-5.2%	0.8%
1Y	-11.3%	-20.1%	6.6%

Return vs Industry: 0N70 exceeded the UK Biotechs industry which returned -20.1% over the past year.

Return vs Market: 0N70 underperformed the UK Market which returned 6.6% over the past year.

Price Volatility

Is 0N70's price volatile compared to industry and market?
0N70 volatility
0N70 Average Weekly Movement	n/a
Biotechs Industry Average Movement	9.6%
Market Average Movement	4.7%
10% most volatile stocks in GB Market	10.3%
10% least volatile stocks in GB Market	2.6%

Stable Share Price: 0N70's share price has been volatile over the past 3 months compared to the UK market.

Volatility Over Time: Insufficient data to determine 0N70's volatility change over the past year.

About the Company

Founded	Employees	CEO	Website
1946	2,464	Peter Janssen	www.biotest.com

Biotest Aktiengesellschaft develops, manufactures, and sells biological and biotechnological pharmaceutical products in Germany and internationally. It operates through three segments: European Union, Rest of the World, and Stateless. The company specializes primarily in the therapeutic areas of clinical immunology, haematology, and intensive care medicine.

Biotest Aktiengesellschaft Fundamentals Summary

How do Biotest's earnings and revenue compare to its market cap?
0N70 fundamental statistics
Market cap	€1.37b
Earnings (TTM)	€68.50m
Revenue (TTM)	€707.00m

15.9x

P/E Ratio

1.5x

P/S Ratio

Is 0N70 overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
0N70 income statement (TTM)
Revenue	€707.00m
Cost of Revenue	€459.30m
Gross Profit	€247.70m
Other Expenses	€179.20m
Earnings	€68.50m

Last Reported Earnings

Sep 30, 2024

Next Earnings Date

Mar 28, 2025

Earnings per share (EPS)	1.73
Gross Margin	35.04%
Net Profit Margin	9.69%
Debt/Equity Ratio	116.4%

How did 0N70 perform over the long term?

See historical performance and comparison

Dividends

0.1%

Current Dividend Yield

2%

Payout Ratio

0N70 Stock Overview

Rewards

Risk Analysis

Biotest Aktiengesellschaft Competitors

LSE:GNS

UK£1.1b

AIM:BVXP

UK£193.6m

AIM:ERGO

UK£701.1m

LSE:HIK

UK£4.2b

Price History & Performance

Recent News & Updates

New major risk - Financial position

Biotest Aktiengesellschaft to Report Fiscal Year 2024 Results on Mar 28, 2025

Second quarter 2024 earnings released: EPS: €0.24 (vs €0.075 loss in 2Q 2023)

Biotest Aktiengesellschaft to Report Q2, 2024 Results on Aug 06, 2024

Biotest Receives FDA Approval for Innovative Yimmugo Immunoglobulin to Treat Primary Immunodeficiencies

First quarter 2024 earnings released: EPS: €0.74 (vs €0.53 loss in 1Q 2023)

Recent updates

New major risk - Financial position

Biotest Aktiengesellschaft to Report Fiscal Year 2024 Results on Mar 28, 2025

Second quarter 2024 earnings released: EPS: €0.24 (vs €0.075 loss in 2Q 2023)

Biotest Aktiengesellschaft to Report Q2, 2024 Results on Aug 06, 2024

Biotest Receives FDA Approval for Innovative Yimmugo Immunoglobulin to Treat Primary Immunodeficiencies

First quarter 2024 earnings released: EPS: €0.74 (vs €0.53 loss in 1Q 2023)

Upcoming dividend of €0.08 per share

Full year 2023 earnings released

Biotest Aktiengesellschaft, Annual General Meeting, May 07, 2024

Investor sentiment deteriorates as stock falls 17%

Biotest Aktiengesellschaft to Report First Half, 2024 Results on Jul 30, 2024

Biotest Aktiengesellschaft to Report Fiscal Year 2023 Results on Mar 28, 2024

Third quarter 2023 earnings released

Biotest Aktiengesellschaft Raises Earnings Guidance for the Year 2023

Biotest AG Appoints Peter Janssen as Chairman of the Management Board, Effective from January 1, 2024

New major risk - Financial position

Biotest Treats First Patient with Severe Community- Acquired Pneumonia in Phase III Trial with Trimodulin

Biotest AG Announces US Food and Drug Administration Accepts Marketing Authorization Application for Immunoglobulin Yimmugo

First quarter 2023 earnings released

Full year 2022 earnings released

Biotest AG Appoints Ainhoa Mendizabal as CFO, with Effect from 15 February, 2023

Biotest Aktiengesellschaft to Report Fiscal Year 2022 Results on Mar 23, 2023

No longer forecast to breakeven

Biotest AG Conducts Clinical Phase III Study PreCyssion with Cmv Hyperimmunoglobulin (Cytotect CP Biotest-) for the Prevention of CMV Infection in the Unborn Child in Germany

Biotest AG Achieves Important Milestone in Phase III Study in Acquired Fibrinogen Deficiency

First quarter 2022 earnings released

Biotest AG Announces Board Changes

Upcoming dividend of €0.04 per share

Grifols, S.A. (BME:GRF) completed the acquisition of a 45.48% stake in Biotest Aktiengesellschaft (XTRA : BIO3) from Tiancheng International Investment Limited.

Biotest Submits Marketing Authorisation Application for IgG Next Generation

Biotest AG Announces Biotest Treats First CMV-Positive Pregnant Woman in Phase III Clinical Trial to Prevent Transmission of CMV Infection to the Unborn Child

Biotest AG Accelerates Trimodulin Development in Hospitalized Covid-19 Patients with Federal Funding from the German Ministries of Health, and Education & Research

Third quarter 2021 earnings released

Forecast to breakeven in 2022

Biotest Receives Approval for Phase III Clinical Trial in Pregnant Women for Prevention of CMV Infection of the Unborn Baby

Biotest Announces the Outcome for Its ESsCOVID (Escape from Severe COVID-19) Trial in Patients with Severe COVID-19

Second quarter 2021 earnings released: €0.11 loss per share (vs €0.16 loss in 2Q 2020)

Biotest AG Provides Earnings Guidance for the Year 2021

Biotest AG Successfully Completes Recruitment for Its Clinical Trial with Trimodulin in Severe Covid-19 Patients

First quarter 2021 earnings released: €0.37 loss per share (vs €0.28 loss in 1Q 2020)

Upcoming dividend of €0.04 per share

Full year 2020 earnings released: €0.80 loss per share (vs €0.13 loss in FY 2019)

Biotest Aktiengesellschaft Provides Earnings Guidance for the Year 2021

Biotest AG Supports Clinical Study with Pentaglobin(R) in Covid-19 at the University Hospital Akh Vienna

New 90-day high: €28.90

Biotest AG Revised Earnings Guidance for the Fiscal Year 2020

Biotest Aktiengesellschaft to Report Fiscal Year 2020 Results on Mar 31, 2021

New 90-day high: €28.60

Biotest Aktiengesellschaft Announces Approval of Biotest Aktiengesellschaft for the Treatment of Severe Bacterial Infections with Concomitant Use of Antibiotics

Biotest Aktiengesellschaft to Report Q1, 2021 Results on May 11, 2021

Third quarter 2020 earnings released: €0.39 loss per share

First half earnings released

Biotest Aktiengesellschaft to Report Q2, 2020 Results on Aug 13, 2020

Shareholder Returns

Price Volatility

About the Company

Biotest Aktiengesellschaft Fundamentals Summary

15.9x

1.5x